HanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye Disease
Hand-out
Press Releases
HanAll Biopharma  
March 6, 2025

HanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye Disease

Batoclimab receives Orphan Drug Designation in Japan, advancing treatment for active Thyroid Eye Disease (TED).Batoclimab, subcutaneous formulation, offers the potential for at-home administration, improving patient convenience and accessibility.Phase 3 study

avatar profile Olean Times Herald

Olean Times Herald


Local & Social